Diamyd Medical gains market research findings to guide U.S. commercial strategy
STOCKHOLM, Jan. 8, 2024 /PRNewswire/ — Market research including initial interviews with US health care practitioners as well as US payers demonstrated a strong willingness to consider prescribing the investigational precision medicine Diamyd® for Type 1 Diabetes and pricing in the range of USD 200,000. Diamyd® is currently being evaluated in the registrational Phase 3 trial […]
United States Ulf Hannelius Company European Phase Iib Kondrad Consulting Group Delivery Networks Idns Company Certified Adviser
Source: bubblear.com